Proinflammatory Cytokines Impair Vitamin D-Induced Host Defense in Cultured Airway Epithelial Cells.
Schrumpf. Jasmijn A JA; Amatngalim. Gimano D GD; Veldkamp. Joris B JB; Verhoosel. Renate M RM; Ninaber. Dennis K DK; Ordonez. Soledad R SR; van der Does. Anne M AM; Haagsman. Henk P HP; Hiemstra. Pieter S PS
Key Findings
- TNFα and IL‑1β exposure lowers vitamin D‑driven LL‑37 production and reduces killing of Haemophilus influenzae
- Inflammation boosts CYP24A1, a vitamin D‑degrading enzyme, without changing the vitamin D receptor or the activating enzyme CYP27B1
- The rise in CYP24A1 is partly driven by specific protein 1 and the EGFR‑MAPK signaling pathway
Practical Outcomes
- Keep chronic airway inflammation low (e.g., manage asthma, avoid pollutants, use anti‑inflammatory supplements) to let vitamin D work best for immune defense. Consider maintaining adequate vitamin D levels and possibly higher dosing if you have persistent inflammation, but be aware that excess inflammation may still limit its effect.
Summary
Inflammation in the lungs (like from asthma or chronic infections) can blunt the benefits of vitamin D, especially its ability to boost the antimicrobial peptide LL‑37 that helps kill bacteria. The study shows that inflammatory signals raise a vitamin‑D‑breaking enzyme (CYP24A1), cutting down the protective effects of both active and inactive vitamin D.
Abstract
Vitamin D is a regulator of host defense against infections and induces expression of the antimicrobial peptide hCAP18/LL-37. Vitamin D deficiency is associated with chronic inflammatory lung diseases and respiratory infections. However, it is incompletely understood if and how (chronic) airway inflammation affects vitamin D metabolism and action. We hypothesized that long-term exposure of primary bronchial epithelial cells to proinflammatory cytokines alters their vitamin D metabolism, antibacterial activity, and expression of hCAP18/LL-37. To investigate this, primary bronchial epithelial cells were differentiated at the air-liquid interface for 14 days in the presence of the proinflammatory cytokines, TNF-α and IL-1β (TNF-α/IL-1β), and subsequently exposed to vitamin D (inactive 25(OH)D<sub>3</sub> and active 1,25(OH)<sub>2</sub>D<sub>3</sub>). Expression of hCAP18/LL-37, vitamin D receptor, and enzymes involved in vitamin D metabolism (CYP24A1 and CYP27B1) was determined using quantitative PCR, Western blot, and immunofluorescence staining. Furthermore, vitamin D-mediated antibacterial activity was assessed using nontypeable Haemophilus influenzae. We found that TNF-α/IL-1β treatment reduced vitamin D-induced expression of hCAP18/LL-37 and killing of nontypeable H. influenzae. In addition, CYP24A1 (a vitamin D-degrading enzyme) was increased by TNF-α/IL-1β, whereas CYP27B1 (that converts 25(OH)D<sub>3</sub> to its active form) and vitamin D receptor expression remained unaffected. Furthermore, we have demonstrated that the TNF-α/IL-1β-mediated induction of CYP24A1 was, at least in part, mediated by the transcription factor specific protein 1, and the epidermal growth factor receptor-mitogen-activated protein kinase pathway. These findings indicate that TNF-α/IL-1β decreases vitamin D-mediated antibacterial activity and hCAP18/LL-37 expression via induction of CYP24A1 and suggest that chronic inflammation impairs protective responses induced by vitamin D.
Study Information
pubmed
2017
10.1165/rcmb.2016-0289oc